Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07221058 · ClinicalTrials.gov registry record · Phase 1
Adaptive Radiation Boost for Rectal Cancer
A Phase 1 study of Rectum Cancer, Adenocarcinoma, sponsored by Fox Chase Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
- 1
- Study location
NCT07221058 is a Phase 1 study of Rectum Cancer, Adenocarcinoma that is actively recruiting participants, run by Fox Chase Cancer Center. The registered enrollment target is 37 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07221058, a Phase 1 study of Rectum Cancer, Adenocarcinoma, is actively recruiting participants, sponsored by Fox Chase Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to find out if giving extra adaptive radiation therapy after standard chemoradiation treatment is safe and helpful for people with rectal cancer. The main questions the study aims to answer are: * Can this approach help target the most aggressive cancer cells more accurately, while protecting nearby healthy tissue? * Can it reduce the side effects that people may experience during treatment? Participants will: * First receive standard treatment: radiation (45 Gy in 25 sessions) along with a chemotherapy pill called capecitabine. * Then get extra radiation using MRI scans every two weeks to adjust the treatment based on how the tumor responds. * Use a small balloon during treatment to help aim the radiation and protect healthy areas. * Finally, receive additional chemotherapy (such as FOLFOX) for four months.
Conditions Studied
Interventions
- RADIATION Adaptive Radiotherapy Boost
Study Locations (1)
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2025-10-24 |
| Est. Completion | 2029-11-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07221058
The ClinicalTrials.gov registry entry for NCT07221058 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rectum Cancer, Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Adaptive Radiotherapy Boost is the first listed.
NCT07221058 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07221058 about?
NCT07221058 is a clinical study titled "Adaptive Radiation Boost for Rectal Cancer". The goal of this clinical trial is to find out if giving extra adaptive radiation therapy after standard chemoradiation treatment is safe and helpful for people with rectal cancer. The main questions the study aims to answer are: * Can this approach help target the most aggressive cancer cells mor...
What is the current status of trial NCT07221058?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2025-10-24. Estimated completion is 2029-11-01.
What conditions does trial NCT07221058 study?
This clinical trial studies the following conditions: Rectum Cancer, Adenocarcinoma.
What interventions are being tested in trial NCT07221058?
The interventions under investigation include: Adaptive Radiotherapy Boost (RADIATION).
Who is sponsoring clinical trial NCT07221058?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07221058 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.